Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.

@article{Mathias2009DoseresponseOR,
  title={Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.},
  author={Anita A Mathias and Steve C. West and James Hoipo Hui and Brian P. Kearney},
  journal={Clinical pharmacology and therapeutics},
  year={2009},
  volume={85 1},
  pages={
          64-70
        }
}
Ritonavir, a potent inhibitor of cytochrome P450 isoform 3A (CYP3A) activity, is frequently used to boost the effects of protease inhibitors at doses of 100-400 mg per day; however, human data regarding the optimal dose required for boosting are limited. This study systematically evaluated the ritonavir dose-response relationship on presystemic and systemic CYP3A metabolism using the human immunodeficiency virus integrase inhibitor elvitegravir and midazolam as probe substrates. Ritonavir… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 44 CITATIONS

Similar Papers

Loading similar papers…